|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 208.6 USD | +3.03% |
|
+6.97% | -19.64% |
| 05:33pm | Guggenheim Adjusts Price Target on Biogen to $255 From $275 | MT |
| Apr. 25 | Biogen Inc. Receives Positive CHMP Opinion for TOFIDence (tocilizumab), a Biosimilar Referencing ROACTEMRA | CI |
Biogen Inc.(NasdaqGS:BIIB) dropped from Russell Top 200 Index
| 1st Jan change | Capi. | |
|---|---|---|
| -19.64% | 29.48B | |
| -4.66% | 87.53B | |
| +1.32% | 40.42B | |
| +57.86% | 25.43B | |
| -17.96% | 11.49B | |
| -43.00% | 11.3B | |
| -9.14% | 11.1B | |
| +5.24% | 8.75B | |
| -8.42% | 7.99B | |
| +1.54% | 7.67B |
BIOGEN INC. 
